Clinical Trial Update: ANTI-SARS-CoV-2 SEROCONVERSIO IN IMMUNE-MEDIATED KIDNEY DISEASES

View source ↗

Summary

A completed clinical trial update examining anti-SARS-CoV-2 seroconversion in patients with immune-mediated kidney diseases, including glomerulonephritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glomerulonephritis

Snippet

Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna | Conditions: Immune-mediated Diseases, Glomerulonephritis | Status: COMPLETED